Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

W H Likosky1, B Fireman, R Elmore

  • 1Department of Neurology, Kaiser Permanente Medical Center, Santa Clara, CA 95051.

Journal of Neurology, Neurosurgery, and Psychiatry
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results.

Epidemiology and infection·2019
Same author

Bcl-2/caspase 3 mucosal imbalance favors T cell resistance to apoptosis in dogs with inflammatory bowel disease.

Veterinary immunology and immunopathology·2014
Same author

Neurochemical evidence for a nigrotegmental GAbAergic projection.

Brain research·2013
Same author

Effects of transcranial focal electrical stimulation via tripolar concentric ring electrodes on pentylenetetrazole-induced seizures in rats.

Epilepsy research·2013
Same author

Critical research needs for managing coral reef marine protected areas: perspectives of academics and managers.

Journal of environmental management·2012
Same author

Neonatal exposure to phenobarbital potentiates schizophrenia-like behavioral outcomes in the rat.

Neuropharmacology·2012
Same journal

Global epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Diagnostic accuracy of a two-cut-off approach using the FAQ/MMSE ratio and FAQ for clinical preselection of patients for anti-amyloid therapy.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Cancer risk and mortality in patients with multiple sclerosis in Finland: a retrospective population-based cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Visuospatial working memory in Huntington's disease: behavioural and structural brain correlates.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Characteristics and outcomes in electric scooter-related traumatic brain injuries in Helsinki.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
See all related articles

A randomized trial found that a short course of immunosuppression with cyclophosphamide did not stabilize chronic progressive multiple sclerosis (MS). Disease progression was similar in patients receiving cyclophosphamide and those receiving folic acid.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Chronic progressive multiple sclerosis (MS) is a debilitating neurological disease.
  • Effective treatments for stabilizing MS progression remain a critical unmet need.

Purpose of the Study:

  • To evaluate the efficacy of a short course of intensive immunosuppression with cyclophosphamide in stabilizing chronic progressive multiple sclerosis.
  • To assess the impact of cyclophosphamide on disability, functional systems, and social roles in MS patients.

Main Methods:

  • A randomized, single-blinded, placebo-controlled trial involving 42 patients with chronic progressive MS.
  • Patients received either cyclophosphamide (n=22) until leucocyte counts fell below 4000/mm3 or folic acid (n=20) as a placebo.
  • Assessments of disability, functional impairment, and social role performance were conducted at baseline and at 12, 18, and 24 months post-therapy.

Related Experiment Videos

Main Results:

  • The primary endpoint at 12 months showed a similar mean increase in disability (0.5 on Kurtzke's Expanded Disability Status Scale) in both the cyclophosphamide and folic acid groups.
  • No substantial benefits were observed in the cyclophosphamide group compared to the placebo group regarding disease stabilization.
  • Immunosuppression with cyclophosphamide was safely administered in an outpatient setting.

Conclusions:

  • A short course of intensive immunosuppression with cyclophosphamide did not demonstrate significant efficacy in stabilizing chronic progressive multiple sclerosis.
  • While safe for outpatient administration, cyclophosphamide did not provide substantial therapeutic benefits for MS progression in this study.